Wei Zhang is an oral and maxillofacial surgeon conducting research on oral cancer, with a particular focus on immunotherapy for oral squamous cell carcinoma (OSCC). He is also interested in how exosomes from oral cancers modulate the tumor microenvironment. Together with his colleagues, Zhang has completed a Phase II clinical trial on locally advanced OSCC, discovering that neoadjuvant Camilizumab combined with TPF chemotherapy improved treatment efficacy in oral cancer patients. Notably, they found that lymph node (LN) metastases of oral cancer were resistant to this neoadjuvant therapy compared to primary cancers, partially due to an increase in SPP1+ macrophages in the LN metastases. Zhang has also observed that hypoxia enhances the secretion of exosomes from oral cancer cells in a HRS-dependent manner, which may educate macrophages into adopting a SPP1+ phenotype.